March 8, 2024 — Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved an additional indication for Wegovy (semaglutide) to reduce the risk of major cardiovascular ...
Cardiovascular Clinical Studies
This channel includes news and new technology innovations from cardiovascular clinical trials. These clinical studies include all cardiac subspecialties.
March 18, 2024 — The Smidt Heart Institute at Cedars-Sinai recently became one of four institutions in the U.S. and the ...
March 18, 2024 — Conformal Medical, Inc. announced that the CLAAS System was featured in a podium presentation at the Ca ...
March 13, 2024 — In the largest randomized clinical trial and first of its kind to date in the United States, a team led ...
March 13, 2024 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...
March 13, 2024 — Silence Therapeutics has announced positive topline 36-week data from the ongoing ALPACAR-360 phase 2 ...
March 8, 2024 — Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved an additional ...
March 6, 2024 — Cleerly, the company on a mission to create a new standard of care to aid in the diagnosis of heart ...
March 6, 2024 — Ensight-AI, a Yale start-up and leader in AI-based cardiovascular diagnostics, announces the receipt of ...
March 6, 2024 — Bodyport Inc., a biomarker-guided predictive care company focused on heart failure, announced data from ...
March 6, 2024 — Lantheus Holdings, Inc. (Lantheus), a radiopharmaceutical company, has announced that the U.S. Food and ...
March 1, 2024 — Prenatal stress is a potential risk factor for cardiovascular disease in offspring later in life. In a ...
March 1, 2024 — Two new studies by Cedars-Sinai investigators support using artificial intelligence (AI) to predict ...
February 29, 2024 — The American College of Cardiology (ACC) will soon be holding its ACC 73rd Annual Scientific Session ...
February 27, 2024 — Aria CV, Inc, a developer of medical devices treating pulmonary hypertension, today announced the ...
February 27, 2024 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & ...